Baltz R H, Seno E T, Stonesifer J, Wild G M
J Antibiot (Tokyo). 1983 Feb;36(2):131-41. doi: 10.7164/antibiotics.36.131.
The efficiencies of bioconversion of twenty-three potential intermediates in the biosynthesis of tylosin were determined with a mutant strain blocked only in tylactone biosynthesis. The results indicated that tylactone, the first intermediate excreted by Streptomyces fradiae, is converted to tylosin by a preferred sequence of reactions which include: (1) addition of mycaminose to the C-5 hydroxyl position of the lactone; (2) hydroxylation of the C-20 methyl group to a hydroxymethyl group; (3) dehydrogenation of the C-20 hydroxymethyl group to a formyl group; (4) hydroxylation of the C-23 methyl group to a hydroxymethyl; (5) addition of 6-deoxy-D-allose to the C-23 hydroxymethyl group; (6) addition of mycarose to the 4'-hydroxyl group of mycaminose; (7) addition of a methyl group to the 2"'-hydroxyl position of demethylmacrocin, and (8) addition of a methyl group to the 3"'-hydroxyl position of macrocin to produce tylosin. The intermediates which lacked both neutral sugars (mycarose and 6-deoxy-D-allose) were biologically unstable, and substantial quantities of these compounds were degraded during standard bioconversion experiments. However, the amount of one such intermediate (O-mycaminosyltylonolide) degraded was substantially reduced when low concentrations of the compound were used for bioconversion, and under these conditions, much higher efficiencies of bioconversion to tylosin were obtained. We have shown that a mutant blocked in hydroxylation of the C-20 methyl group is also blocked in the further dehydrogenation of the C-20 hydroxymethyl group to a formyl group, and have confirmed in in vitro studies that the 2"'-O-methylation of demethylmacrocin must proceed the 3"'-O-methylation of macrocin to produce tylosin.
利用仅在泰乐菌素内酯生物合成中受阻的突变菌株,测定了泰乐菌素生物合成中23种潜在中间体的生物转化效率。结果表明,弗氏链霉菌分泌的首个中间体泰乐菌素内酯通过一系列优先反应转化为泰乐菌素,这些反应包括:(1) 氨基糖胺添加到内酯的C-5羟基位置;(2) C-20甲基羟基化为羟甲基;(3) C-20羟甲基脱氢为甲酰基;(4) C-23甲基羟基化为羟甲基;(5) 6-脱氧-D-阿洛糖添加到C-23羟甲基上;(6) 霉糖添加到氨基糖胺的4'-羟基上;(7) 甲基添加到去甲基马红霉素的2"'-羟基位置;(8) 甲基添加到马红霉素的3"'-羟基位置以生成泰乐菌素。缺乏中性糖(霉糖和6-脱氧-D-阿洛糖)的中间体在生物学上不稳定,在标准生物转化实验中大量此类化合物会降解。然而,当使用低浓度的一种此类中间体(O-氨基糖胺基泰洛内酯)进行生物转化时,其降解量显著减少,在此条件下,获得了更高的泰乐菌素生物转化效率。我们已经表明,在C-20甲基羟基化中受阻的突变体在C-20羟甲基进一步脱氢为甲酰基的过程中也受阻,并且在体外研究中证实,去甲基马红霉素的2"'-O-甲基化必须先于马红霉素的3"'-O-甲基化以生成泰乐菌素。